Functional Outcome Measures in Children with Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 442

References
[1] Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet
2004;363(9418):1377-85.
[2] Roughley PJ, Rauch F, Glorieux FH. Osteogenesis imperfecta -
clinical and molecular diversity. Eur Cell Mater 2003;5:41-7.
[3] Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteo-
genesis imperfecta. J Med Genet 1979;16(2):101-16.
[4] Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S,
et al. Prolyl 3-hydroxylase 1 deiciency causes a recessive met-
abolic bone disorder resembling lethal/severe osteogenesis
imperfecta. Nat Genet 2007;39(3):359-65.
[5] Astrom E, Soderhall S. Beneicial effect of long term intravenous
bisphosphonate treatment of osteogenesis imperfecta. Arch Dis
Child 2002;86(5):356-64.
[6] Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G,
Travers R. Cyclic administration of Pamidronate in chil-
dren with severe osteogenesis imperfecta. N Engl J Med
1998;339(14):947-52.
[7] Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and
density in children and adolescents with osteogenesis imper-
fecta: effect of intravenous Pamidronate therapy. J Bone Miner
Res 2003;18(4):610-4.
[8] Bjorck-Akesson E, Wilder J, Granlund M, et al. The international
classiication of functioning, disability and health and the ver-
sion for children and youth as a tool in child habilitation/early
childhood intervention - feasibility and usefulness as a common
language and frame of reference for practice. Disabil Rehabil
2010(32 Suppl. 1):S125-38.
[9] Engelbert RH, van der Graaf Y, Beemer FA, Helders PJ.
Osteogenesis imperfecta in childhood: impairment and disabil-
ity. Pediatrics 1997;99:1-7.
[10] Engelbert RH, Uiterwaal CS, Gerver WJ, van der Net JJ, Pruijs
HE, Helders PJ. Osteogenesis imperfecta in childhood: impair-
ment and disability. A prospective study with 4-year follow-up.
Arch Phys Med Rehabil 2004;85:772-8.
[11] President's Council on Physical Fitness. Definitions: health, it-
ness, and physical activity. Research Digest, 2000.

[19] Van Brussel M, Takken T, Uiterwaal CS, Pruijs HJ, Van der Net J,
Helders PJ, et al. Physical training in children with osteogenesis
imperfecta. J Pediatr 2008;152(1):111-6.
[20] van Brussel M. General discussion van Brussel M, editor.
Physical itness and training in chronic childhood conditions
[PhD thesis]. Utrecht, the Netherlands: Utrecht University; 2008.
p. 148-66.
[21] Faigenbaum AD, Westcott WL, Loud RL, Long C. The effects of
different resistance training protocols on muscular strength and
endurance development in children. Pediatrics 1999;104:e5.
[22] Schoenau E. Bone mass increase in puberty: what makes it hap-
pen? Horm Res 2006;65(Suppl. 2):2-10.
[23] Bleck EE. Nonoperative treatment of osteogenesis imper-
fecta: orthotic and mobility management. Clin Orthop
1981;159:111-22.
[24] Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs H, Helders PJ.
Osteogenesis imperfecta in childhood: prognosis for walking.
J Pediatr 2000;137:397-402.
[25] Sillence DO, Morley K, Ault JE. Clinical management of osteo-
genesis imperfecta. Connect Tissue Res 1995;31:15-21.
[26] Graf A, Hassani S, Krzak J, Caudill A, Flanagan A,
Bajorunaite R, et al. Gait characteristics and functional assess-
ment of children with type I osteogenesis imperfecta. J Orthop Res
2009;27(9):1182-90.
[27] Phillipi CA, Remmington T, Steiner RD. Bisphosphonate ther-
apy for osteogenesis imperfecta. Cochrane Database Syst Rev
2008(4):CD005088.
[28] Kok DH, Sakkers RJ, Janse AJ, Pruijs HE, Verbout AJ, Castelein
RM, et al. Quality of life in children with osteogenesis imper-
fecta treated with oral bisphosphonates (Olpadronate): a
2-year randomized placebo-controlled trial. Eur J Pediatr
2007;166(11):1155-61.
[29] Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE,
Chernoff EJ, et al. Controlled trial of Pamidronate in children
with types III and IV osteogenesis imperfecta conirms vertebral
gains but not short-term functional improvement. J Bone Miner
Res 2005;20(6):977-86.
[30] Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D,
Browne R, et al. Impact of alendronate on quality of life in
children with osteogenesis imperfecta. J Pediatr Orthop
2005;25(6):786-91.
[31] Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G,
Duboeuf F, et al. Effects of oral alendronate on BMD in adult
patients with osteogenesis imperfecta: a 3-year randomized
placebo-controlled trial. J Bone Miner Res 2006;21(2):300-6.
[32] Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer
JW, Bleijenberg G. Dimensional assessment of chronic fatigue
syndrome. J Psychosom Res 1994;38:383-92.
[33] Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs HE, Helders
PJ. Osteogenesis imperfecta: proiles of motor develop-
ment as assessed by a postal questionnaire. Eur J Pediatr
2000;159(8):615-20.
[34] Alcausin, Ault J, Pacey V, Briody J, McQuade M, Bridge C. et al.
Intravenous pamidronate treatment in children with moderate
to severe osteogenesis imperfecta started under 3 years of age.
Horm Res Paediatr 2013. Epub ahead of print.

[12] Boot AM, de Coo RFM, Pals G, de Muinck Keizer-Schrama

SMPF. Muscle weakness as presenting symptom of osteogenesis
imperfecta. Eur J Pediatr 2006;165:392-4.

[13] Engelbert RH, Gulmans VA, Uiterwaal CS, Helders PJ.

Osteogenesis imperfecta in childhood: perceived competence in
relation to impairment and disability. Arch Phys Med Rehabil
2001;82(7):943-8.

[14] Takken T, Terlingen HC, Helders PJ, Pruijs H, Van der Ent CK,

Engelbert RH. Cardiopulmonary itness and muscle strength
in patients with osteogenesis imperfecta type I. J Pediatr
2004;145:813-8.

[15] Caudill A, Flanagan A, Hassani S, Graf A, Bajorunaite R,

Harris G, et al. Ankle strength and functional limitations in
children and adolescents with type I osteogenesis imperfecta.
Pediatr Phys Ther 2010;22(3):288-95.

[16] Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel

M, et al. Rapid increase in grip force after start of pamidronate
therapy in children and adolescents with severe osteogenesis
imperfecta. Pediatrics 2003;111:e601-3.

[35] Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M,

Pruijs H, et al. Skeletal effects and functional outcome
with olpadronate in children with osteogenesis imper-
fecta: a 2-year randomised placebo-controlled study. Lancet
2004;363(9419):1427-31.

[17] Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect

of intravenous pamidronate therapy on functional abilities and
level of ambulation in children with osteogenesis imperfecta.
J Pediatr 2006;148(4):456-60.

[18] Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imper-

fecta type VI in childhood and adolescence: effects of cyclical
intravenous Pamidronate treatment. Bone 2007;40(3):638-44.

[36] Montpetit K, Dahan-Oliel N, Ruck-Gibis J, Fassier F, Rauch F,

Glorieux F. Activities and participation in young adults with
osteogenesis imperfecta. J Pediatr Rehabil Med 2011;4(1):13-22.